The antibody-binding-test, a useful method for quantitative determination of inactivated rabies virus antigen

Barth, R; Gross-Albenhausen, E; O, Jaeger; L, Milcke

doi:10.1016/s0092-1157(81)80068-6

Cited by 38 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results obtained on days 21 and 42 showed that the suckling mouse brain vaccine produced with the PV strain performed better (P<0.01) than the one produced with the CVS strain, although both had a very similar NIH potency titer. Actually, their relative potencies may not have been equivalent, since the NIH test has been shown to have very low reproducibility (8,9).…”

mentioning

confidence: 99%

Short duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine

Zanetti

Consales²,

Rodrigues-da-Silva³

et al. 1998

Braz J Med Biol Res

View full text Add to dashboard Cite

The human anti-rabies pre-exposure treatment currently used in Brazil, employing a 1-ml dose of suckling mouse brain vaccine (SMBV) administered on days 0, 2, 4 and 28, was compared to an alternative treatment with two 1 ml-doses on day 0, and one 1 ml-dose injected on days 7 and 21. The latter induced higher virus-neutralizing antibody (VNA) titers on day 21. Both Brazilian rabies vaccines produced with PV or CVS rabies virus strains were tested. Two additional volunteer vaccinee groups, receiving the pre-exposure and the abbreviated postexposure schedules recommended by the WHO using cell-culture vaccine (CCV) produced with PM rabies virus strain, were included as reference. The VNA were measured against both PV and CVS strains on days 21, 42 and 180 by the cell-culture neutralization microtest. The PV-SMBV elicited higher seroconversion rates and VNA by day 21 than the CVS-SMBV. Both, however, failed to induce a long-term immunity, since VNA titers were <0.5 IU/ml on day 180, regardless of the schedule used. Cell-culture vaccine always elicited very high VNA on all days of collection. When serum samples from people receiving mouse brain tissue were titrated against the PV and CVS strains, the VNA obtained were similar, regardless of the vaccinal strain and the virus used in the neutralization test. These results contrast with those obtained with sera from people receiving PM-CCV, whose VNA were significantly higher when tested against the CVS strain.

show abstract

mentioning

confidence: 99%

Short duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine

Zanetti

Consales²,

Rodrigues-da-Silva³

et al. 1998

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…This has, however, led to only limited numbers of proposals for actual replacement. So far, the modified antibody binding test (ABT) (Barth et al, 1981;Barth et al, 1990) and the single radial diffusion test (SRD) (Ferguson and Schild, 1982;Ferguson et al, 1984;Ferguson and Heath, 1992) were proposed as alternatives. Their use is restricted to GP measurement by polyclonal antibodies and is not applicable to adjuvanted vaccines.…”

Section: Discussionmentioning

confidence: 99%

Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing

Rooijakkers

Uittenbogaard

Groen

et al. 1996

Journal of Virological Methods

View full text Add to dashboard Cite

Potency control of inactivated rabies vaccines for human and veterinary application is usually undertaken by vaccination-challenge tests (e.g. the mouse potency test). For practical and ethical reasons there is an urgent need to replace in vivo potency control procedures, at least in part, by reliable methods of in vitro potency testing. Quantitative ELISA systems for potency control were developed using monoclonal antibodies (MAbs) directed to the glycoprotein (GP) and to the nucleoprotein (NP) of the virus. Although immuno-capture and competition ELISAs for GP measurement had almost equal sensitivity (detection level GP < 0.1 IU), the competition data showed the best correlation with potency values when a panel of rabies vaccines for human use was tested (r = 0.88, n = 10). The NP values for this panel of vaccines in the competition system (detection level NP < 1 IU) also correlated well with potency values (r = 0.90, n = 10). The competition system proved to be best also with liquid adjuvanted veterinary rabies vaccines of LEP, PM, PV and SAD origin. The implementation of ELISA systems for potency control of rabies vaccines is discussed.

show abstract

“…To date, limited information is available on possible alternatives for the actual replacement of the mouse potency test (2,3,10,11) that would be independent of laboratory animal use, which causes most of the aforementioned problems. The alternative in vitro methods that have been considered include the modified antibody binding test (4,5), the single radial immuno-diffusion test (12,13), and ELISAs (1, 21,22,23,29,31). These methods can generally not be used for adjuvanted vaccines and were used to measure the GP content.…”

Section: Discussionmentioning

confidence: 99%

Potency of veterinary rabies vaccines in the Netherlands: A case for continued vigilance

Rooijakkers

Nieuwenhuijs

Vermeulen

et al. 1996

Veterinary Quarterly

View full text Add to dashboard Cite

The antibody-binding-test, a useful method for quantitative determination of inactivated rabies virus antigen

Cited by 38 publications

References 1 publication

Short duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine

Short duration of neutralizing antibody titers after pre-exposure rabies vaccination with suckling mouse brain vaccine

Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing

Potency of veterinary rabies vaccines in the Netherlands: A case for continued vigilance

Contact Info

Product

Resources

About